{
    "medicine_id": "0df8b0a4e7099dbab9bd94255d607b0132b30351",
    "platform_id": "DB04907",
    "metadata": {
        "name": "Natrecor 1 5 mg 5mL Injection powder lyophilized for solution",
        "composition": "1 5 mg 5mL Sitimagene ceradenovec",
        "clinical_particulars": {
            "therapeutic_indications": "Intended for the treatment of brain cancer",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "EG009 is comprised of a gene encased in a virus vector Vectors transfer their gene payload into target cells a process known as transfection which use this new genetic material as a blueprint for the production of new beneficial proteins EG009 uses a well established adenoviral vector Ad5 to introduce the gene that causes cells to express a protein called thymidine kinase TK Following the standard surgery to remove the solid tumour mass EG009 is injected through the wall of the cavity left behind by the surgical removal of the solid tumour into the surrounding healthy brain tissue In the following days the healthy cells in the wall of the cavity express TK Five days after surgery the drug ganciclovir GCV is given to the patient as part of the overall EG009 treatment regimen Neither TK nor GCV is individually active but they react together to produce a substance which destroys cells when they try to divide Since cell division is a key characteristic of cancer and the normal brain cells are not dividing cells that try to divide to form a new tumour around the site of the removal of the original tumour are targeted for destruction by the EG009 treatment EG009 thus works by harnessing healthy cells to produce the substances necessary to destroy newly growing cancer cells",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Sitimagene ceradenovec"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Sitimagene ceradenovec"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Sitimagene ceradenovec"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Sitimagene ceradenovec"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}